We evaluated the efficacy of topical Myolaxin (capsaican ointment, Geno, Mumbai) ointment over EMLA (eutectic mixture of lignocaine, prilocaine; Neon, Goa) cream for attenuating venous cannulation pain in this prospective, randomised, double blind study. Sixty adult patients undergoing elective laparoscopic cholecystectomy were randomly assigned into two equal groups. Group I (EMLA) received EMLA cream, whereas Group II (Myolaxin) received Myolaxin ointment. For both groups the cream was applied at the venous cannulation site (dorsum of the non-dominant hand) one hour prior to venous cannulation and was covered with an occlusive dressing. Following venous cannulation patients were asked if they felt pain during venous cannulation. If the answer was yes, they were asked to rate the severity of venous cannulation pain using a Visual Analogue Scale (VAS) of 0-10. The incidence of venous cannulation pain was similar between groups: in the EMLA group 65% (18/28) compared to 67% (20/30) in the Myolaxin group (P=0.19). The severity of pain (median VAS with inter quartile range) was also similar between the groups: in the EMLA group 1.5 (3) compared to 1.5 (2) in the Myolaxin group (P=0.46). As the topical application of Myolaxin ointment is cheaper than EMLA and has similar efficacy, it may be a suitable alternative for reducing the incidence and severity of venous cannulation pain.
Pain during venous cannulation is unpleasant and often frightening for patients. In fact, discomfort among the 33 low morbidity clinical outcomes by expert anaesthesiologists when both clinical importance and frequency were considered 1 . Various methods to reduce venous cannulation pain have been used such as application of EMLA cream, diclofenac patch, ibuprofen, piroxicam, lignocaine, ethyl chloride spray, nitrous oxide, ice and distraction tactics, with variable results [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Topical capsaicin has been successfully used in the management of chronic non-neurogenic and myofascial pain 13 . We therefore, ointment for attenuating venous cannulation pain and compare it with the more standard technique of topical EMLA cream 5 .
METHODS
After approval from our institute's ethical committee and written informed consent from patients, this prospective, randomised, double blind study was conducted. The study consisted of 60 adults (15 to 60 years), ASA physical status I and II, of either gender, undergoing elective laparoscopic cholecystectomy. Patients with peripheral neuropathy, long-term consumption of analgesics, abnormal skin condition (broken skin, infection, scar, psoriasis, eczema) at the site of venous puncture, allergy or any other side effect secondary to application of cream, and mental disorder were excluded.
As about 63% of patients are reported to be painfree during venous cannulation following topical EMLA 14 , for the purposes of this study we assumed that following Myolaxin cream only 25% of patients would not experience venous cannulation pain. With these assumptions, our power analysis indicated that with =0.05 and =0.80, we would need to enrol 26 patients in each group. To take care of any dropout at any stage we enrolled 30 patients in each group.
The patients were randomly assigned into two equal groups with the help of computer generated random numbers. Group I (EMLA) received EMLA cream (NEON Laboratories LTD, Mumbai, India), whereas Group II (Myolaxin) received Myolaxin ointment (containing oleoresin capsicum equivalent to capsicum 0.075% w/w, methylsalicylate IP 20% w/w, menthol IP 10% w/w, camphor USP 5% w/w and eucalyptus oil IP 5% w/w; manufactured by Geno Pharmaceutical Ltd, Goa, India). All patients were premedicated with oral lorazepam 2 mg the night before surgery and again at 0600 hours on the morning of surgery.
Depending upon the results of the randomisation, a blinded investigator (DG) not involved in the anaesthetic applied cream to a 10 cm 2 area (site of venous cannulation) on the dorsum of the nondominant hand of study patients in the preoperative area one hour prior to shifting them to the operating theatre (OT). Following its application, the cream was covered by standard occlusive transparent dressings. The study was conducted between 0900 and 1100 on pain sensitivity 15 . Prior to shifting the patients to the OT, the occlusive dressings were removed, the area cleaned with an alcohol swab and the venous cannulation site marked by the blinded investigator. At this point patients were asked to report if they felt any abnormal sensations like burning, cold or stinging at the site of cream application and to grade its severity as mild, moderate or severe. In the OT IV cannulation was performed following manual venous occlusion by an experienced anaesthesiologist using an 18 gauge cannula (Poly Medicure Ltd, India) and TM , 3M Health Care, Neuss, Germany). Patients who withdrawn from the study.
Following venous cannulation, patients were asked if they experienced pain. If they experienced pain, they were asked to rate its severity using a Visual Analog Scale (VAS) of 0-10. All the patients were observed for 24 hours for any local blanching, erythema or swelling at the site of venous cannulation.
Data regarding incidence of pain were compared with test of proportions (Z test). The severity of pain in those patients who experienced pain in the two groups was compared using a Mann Whitney U test. The package SPSS 14.0 (SPSS Inc, Chicago, IL, U.S.A.) was used for statistical analysis. P <0.05 was
RESULTS
Two patients belonging to the EMLA group could withdrawn from the study. The data of dropout patients were included in the demographic data of our study, but were excluded from the subsequent analysis. The groups were similar with regard to age, gender, weight and height distribution ( Table 1) .
The incidence of venous cannulation pain was similar between the two groups: EMLA group 65% (18/28) compared to 67% (20/30) in Myolaxin group (P <0.05). The severity of venous cannulation pain (median VAS with interquartile range) was also similar between groups: EMLA group 1.5 (3) compared to 1.5 (2) in the Myolaxin group (P=0.46).
In the Myolaxin group there was a higher incidence of feeling of cold, 16.7% (5/30) or stinging, 13.3% (4/30), at the site of ointment application than in the EMLA group (P=0.02 and P=0.04 respectively) ( Table 3 ). The severity of cold and stinging was mild in all patients who reported these side-effects. None Data are presented either in number of patients or mean ± SD. 
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Anaesthesia and Intensive Care, Vol. 35, No. 5, October 2007 of the patients in any group reported burning. There was a higher incidence of blanching, 64% (18/28), and erythema, 35.7% (10/28), in the EMLA group compared to the Myolaxin groups (none) (P <0.001 and P <0.001 respectively). None of the patients in either group had swelling at the site of ointment application.
DISCUSSION
The incidence and severity of venous cannulation pain were similar in the Myolaxin and EMLA groups (P >0.05). Therefore, one can deduce that topical application of Myolaxin cream is as effective as the more standard technique of topical EMLA for attenuating venous cannulation pain when applied at the proposed venous cannulation site one hour prior to cannulation. EMLA was associated frequently with local blanching (64%) or erythema (36%), which were not observed with Myolaxin. However, Myolaxin was occasionally associated with a mild feeling of cold (17%) or stinging (13%).
Topical capsaicin has been effectively used in the management of myofascial pain, osteoarthritis, postherpetic neuralgia, trigeminal neuralgia, bracheoradial pruritus and nodular prurigo 13 . Capsicum ointment produces topical analgesia by inhibiting high voltage activated calcium channel current (ICa) using trigeminal ganglion neurones and a heterologous expression system 16 . It is well established that repeated application of capsaicin cream depletes be the principal transmitter of nociceptive impulses in type C sensory neurones 17 . All the ingredients of the Myolaxin ointment (capsicum, methylsalicylate, menthol, camphor and eucalyptus oil) have been reported to produce analgesia via counter-irritation 18 . Side-effects associated with capsicum are feeling of warmth, stinging or sensation of burning and redness at the site of application. While capsaicin is main ingredient of Myolaxin cream, we are not in a position to comment whether the observed analgesic effect is caused by capsaicin alone or if other components of the preparation are involved. This needs to be explored in further trials.
The EMLA cream (eutectic mixture of 2.5% lignocaine with 2.5% prilocaine) is an effective method for prevention of cannulation pain, but the vasoconstrictive effect of EMLA at the time of venous cannulation is associated with transient blanching and when the vasoconstrictive effect wears off, there is a generalised vasodilatation, which may lead to erythema and local swelling 19 . EMLA cream has also been reported to be effective in reducing spinal puncture pain 20 . Side effects associated with EMLA are methaemoglobinaemia, erythema, urticaria, allergic contact dermatitis, irritant contact dermatitis, hyperpigmentation and purpura 21, 22 .
A 15 g tube of Myolaxin costs around US$1 and it could be comfortably used in >100 patients for attenuating venous cannulation pain if there was no cross-infection risk. However, the cost of EMLA is about US$1 per patient. Therefore, Myolaxin might be much more cost-effective than EMLA. Nevertheless, we would caution against multiple uses of the same tube which would have the potential for cross-infection. Hopefully, a smaller individual package (e.g. 1 g) could be prepared which would still be cost-effective.
In conclusion, topical Myolaxin appears to be as effective as topical EMLA for attenuating the incidence and severity of venous cannulation pain and may be a more cost-effective option. 
